EndoTool SubQ

by Monarch Medical Technologies, a Glooko Company  · Based in United States → — Personalized insulin management for healthcare enterprises.
Endocrinology Hospital Medicine Pediatrics

Contact vendor
Regulatory Status Disclosed

Overview

EndoTool SubQ, developed by Monarch Medical Technologies (now part of Glooko as of September 23, 2025), is a software application designed to provide clinical decision support for subcutaneous insulin administration. It is used to manage blood glucose levels in both adult and pediatric patients (age 2 years and above and 12 kg or more). The tool utilizes proprietary model predictive control technology and feedback mathematics to model, predict, and adjust to each patient’s unique physiology and individual response to insulin, recommending the safest, most effective patient-specific dose.

EndoTool SubQ considers various factors that impact insulin response, including blood glucose level, height, weight, type of diabetes mellitus, age, sex, creatinine levels, steroids, carbohydrate intake, and ordered insulin. The software aims to reduce and eliminate correctional dosing, promote mealtime dosing, and prevent hypoglycemia by recommending supplemental carbohydrates if needed. As part of the broader EndoTool platform, it facilitates safe and easy transitions between intravenous and subcutaneous insulin therapies. The technology originated in 2003 with MD Scientific, which laid the groundwork for the EndoTool glucose management system.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Patient-specific insulin dosing recommendations
  • Model predictive control technology
  • Feedback mathematics for modeling and predicting insulin response
  • Adjusts to individual patient physiology
  • Considers various patient factors (BG, height, weight, diabetes type, age, sex, creatinine, steroids, carb intake, ordered insulin)
  • Reduces and eliminates correctional dosing
  • Promotes mealtime dosing
  • Recommends supplemental carbohydrates for hypoglycemia prevention
  • Supports adult and pediatric patients (age 2 and above)
  • Seamless transition between IV and SubQ insulin therapies (as part of EndoTool platform)

Use Cases

  • Inpatient subcutaneous insulin management
  • Hyperglycemia treatment in hospitalized patients
  • Hypoglycemia prevention in hospitalized patients
  • Transitioning patients from IV to subcutaneous insulin therapy
  • Standardizing insulin dosing protocols in hospitals
  • Improving glycemic control and patient safety in hospitals

What Physicians Need to Know

Key Capabilities
EndoTool SubQ provides personalized insulin dosing recommendations for subcutaneous insulin delivery in both adult and pediatric patients (age 2 and older). It utilizes model predictive control technology and feedback mathematics to model, predict, and adapt insulin dosing based on various patient variables. These variables include blood glucose, insulin order, A1c, type of diabetes, height, weight, creatinine, age, gender, carbohydrate intake, and previous glucose responses. The system aims to provide the safest, most effective patient-specific dose, including basal/bolus and correction recommendations, and can adjust for low or consistently high readings to reduce or eliminate correctional dosing. It also features an optional insulin-on-board (IOB) calculation to mitigate hypoglycemia risk.
Clinical Utility
EndoTool SubQ is designed to improve inpatient glycemic management by standardizing insulin management and reducing the risk of severe hypoglycemia and hyperglycemia. It has been shown to significantly reduce hypoglycemic events (glucose readings <70 mg/dL) and severe hypoglycemia (glucose readings <40 mg/dL). The system helps clinicians achieve better glucose control, which can improve post-procedure recovery outcomes and reduce infections. It also aids in the safe and easy transition of patients from intravenous to subcutaneous insulin therapy.
Integration Options
EndoTool SubQ is designed to integrate with Electronic Medical Records (EMR) systems to streamline clinical workflows and eliminate charting duplication. It can also function as a stand-alone system if EHR integration is not feasible for a hospital.
Compliance Status
EndoTool SubQ has received U.S. Food and Drug Administration (FDA) 510(k) clearance as a Class II medical device. It is also HIPAA-compliant.
Pricing Model
Monarch Medical Technologies offers tailored pricing models to fit an organization's requirements and budget.
User Experience
The software is designed for ease of use, with a focus on efficient and effective clinical workflow. Nurses follow a simple three-step process for safe dose recommendations. The system provides real-time, data-driven insulin recommendations, reducing the need for manual adjustments and increasing nurse confidence. Initial concerns from nursing staff regarding higher insulin doses and unfamiliarity with basal insulin use were addressed through extensive education.
Support Quality
Comprehensive training is an integral part of the implementation package, including on-site sessions, online modules, and continuous support.
Implementation Complexity
EndoTool is designed for flexible integration and rapid deployment. While there may be upfront end-user training and IT implementation costs, the system has been well-received. Assessing clinical adoption and addressing potential resistance or misconceptions during implementation is important for continuous improvement.
Evidence Base
EndoTool SubQ is backed by clinical evidence demonstrating its effectiveness in reducing hypoglycemia and improving glycemic control. Studies have shown significant reductions in hypoglycemic events and severe hypoglycemia. It has been shown to be safer than standard fixed-dose insulin infusion protocols for patients with DKA or HHS, with significantly lower incidence of hypoglycemia. The system has been proven to reduce the risk of severe hypoglycemia to virtually zero.
Physician Tip

EndoTool SubQ offers a patient-specific approach to insulin dosing, moving beyond traditional sliding-scale protocols to provide individualized and adaptive recommendations. Pay close attention to the system's recommendations, as they are based on a comprehensive analysis of patient variables and are designed to prevent both hypoglycemia and hyperglycemia. The system's ability to facilitate safe transitions from IV to SubQ insulin therapy is a key advantage for managing inpatient diabetes. Utilize the provided training and support to maximize the tool's effectiveness and ensure optimal patient outcomes. Regularly review the analytics provided by EndoTool to assess clinical adoption and identify areas for continuous improvement in glycemic management within your institution.

EndoTool SubQ is designed for integration with existing Electronic Medical Records (EMR) systems, such as Cerner, to streamline workflows and avoid duplicate charting. This integration allows for a more seamless flow of patient data and insulin dosing recommendations. For healthcare facilities where direct EHR integration is not immediately feasible, EndoTool SubQ can also operate as a standalone system, offering flexibility in deployment based on the hospital's infrastructure and needs.

Details

Category Endocrinology & Metabolic AI, Pharmacology & Dosing AI
Pricing Contact vendor
DeploymentCloud-based (browser-based) and potentially thick client options.
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Endocrinology, Hospital Medicine, Pediatrics

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2015-04-24K142918 510(k)EndoTool SubQ

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate EndoTool SubQ

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for EndoTool SubQ.

Loading videos...

View all on YouTube

Frequently Asked Questions

EndoTool SubQ uses advanced proprietary technology with feedback mathematics and model predictive control to individualize insulin dosing. It considers various patient factors like blood glucose levels, height, weight, type of diabetes, age, sex, creatinine levels, steroid use, and carbohydrate intake to recommend precise basal/bolus and correction subcutaneous insulin doses.
EndoTool SubQ aims to improve patient safety by providing individualized insulin dose recommendations, which helps reduce the risk of both hyperglycemia and hypoglycemia. It standardizes insulin management protocols, reduces variability in care, and can facilitate safe transitions between intravenous and subcutaneous insulin therapy.
Yes, EndoTool SubQ is FDA-cleared. This clearance indicates that the system has been reviewed by the FDA and determined to be safe and effective for its intended use in managing subcutaneous insulin dosing for hospitalized adult and pediatric patients (age 2 years and above).
Healthcare organizations maintain full control over clinical parameters and goal ranges within EndoTool SubQ, allowing them to align the system with their internal protocols and compliance requirements. This configurability ensures that the AI-driven recommendations adhere to established institutional guidelines.
Alternatives to EndoTool SubQ include other FDA-cleared glycemic management systems like Glytec's Glucommander, which also offers IV and subcutaneous insulin dosing. Hospitals may also utilize EHR-native insulin calculators, or manual protocols and paper-based workflows, though these may lack the patient-specific AI-driven precision of systems like EndoTool SubQ.
While EndoTool SubQ offers significant advantages, specific detailed limitations are not extensively published. However, like any clinical decision support tool, it assists licensed healthcare professionals and does not replace clinical judgment. The effectiveness can also depend on the initial conservative parameter settings by clinicians during rollout.
The cost of EndoTool SubQ varies depending on the specific needs and healthcare setting of the organization. Monarch Medical Technologies provides tailored pricing models to best fit an organization's requirements and budget.

Related Tools

EatLove
EatLove
Endocrinology & Metabolic AI
EatLove is an AI-powered digital health platform that provides personalized nutrition plans and meal recommendations for patients, designed to be used by healthcare professionals.
CGM Analytics (CompuGroup Medical)
CompuGroup Medical
Endocrinology & Metabolic AI
CGM Analytics is a healthcare data aggregation and analytics software solution for physician practices to analyze patient data and manage populations.
AI Health Clinic
AI Health Clinic
Clinical Decision Support & Reference
AI Health Clinic provides AI that amplifies clinicians by analyzing CGM, body composition, labs, and wearables to create a metabolic index, triage patients, and draft care plans for physician approval.
90Health
90Health
Endocrinology & Metabolic AI
90Health offers a complete digital solution for managing chronic disease with AI-powered programs, cognitive behavioral lessons, data monitoring, compassionate coaching, and care coordination.
Twin Health
Twin Health
Endocrinology & Metabolic AI
Twin Health uses AI Digital Twin technology to provide precision care for metabolic conditions, offering real-time monitoring, AI-driven insights, and personalized plans to support diabetes remission and medication reduction.
Tidepool Loop
Tidepool
Endocrinology & Metabolic AI

See all Endocrinology & Metabolic AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-10 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.